A broad-spectrum, bactericidal antibiotic of the fluoroquinolone drug class that treats bacterial infections. (Podder & Sadiq, 2020) A valuable antimicrobial agent that has high levels of susceptibility among Gram-negative, Gram-positive including penicillin-resistant strains of Streptococcus pneumonia and atypical pathogens. (Antoni Torres, 2012) More active against gram-positive pathogens than ciprofloxacin. (Miriam Hurst, 2002) As effective as gatifloxacin, clarithromycin, azithromycin or amoxicillin/clavulanic acid in patients with mild to severe community-acquired pneumonia. (Miriam Hurst H. M., 2002) An effective therapy as intravenous imipenem/cilastatin in suspected bacteraemia patients. (Miriam Hurst H. M., 2002) A therapeutic regimen in patients with uncomplicated skin and skin structure infections, and complicated urinary tract infections. (Miriam Hurst H. M., 2002) Achieves 64.7% clinical success rate as compared with 41.2% with comparator treatment (imipenem/cilastatin followed by ciprofloxacin) in patients diagnosed with nosocomial pneumonia. (Alan M Tennenberg, 2006) Exhibits good clinical and microbiological efficacy for use in lower respiratory tract infections that are caused by Streptococcus pneumoniae. (Guoying Cao, 2020) Demonstrates antibacterial efficacy against a variety of infections, including upper and lower respiratory tract, genitourinary, obstetric, gynecological, and skin and soft tissues. (R Davis, 1994) An attractive option for the treatment of at-risk patients with serious respiratory tract infections including community-acquired pneumonia and acute exacerbations of chronic bronchitis. (Rafael Cantón, 2006)

A combi pack is used to prevent stomach and intestinal ulcers caused by bacterial infection with helicobacter pylori. Effectively eradicates helicobacter pylori infection in patients with peptic and duodenal ulcer disease. Ensures high rates of ulcer healing and helicobacter pylori eradication. Esomeprazole-based triple therapy demonstrates a higher eradication rate than pantoprazole-based regimen. Relieves acidity and discomfort related to the infection. Shows a more rapid onset of acid-suppressant effect than omeprazole. (Dr L. Laine, 2002)

An antibacterial is used to treat various bacterial infections of the urinary tract, ear, throat, lungs, and uncomplicated gonorrhea. Enhances the activity of cefixime against bacteria and decreases bacterial resistance. A viable option for the treatment of uncomplicated community-acquired infections. (Deepti Rawat, 2009) An attractive alternative to amoxicillin for patients with acute otitis media. (Bluestone, 1993) Offers the additional benefit of covering beta-lactamase-producing strains of bacteria that are resistant to many penicillins. (D R Edelstein, 1993) Exhibits good activity against most pathogens causing urinary tract infections. (Modai, 1989) A suitable alternative to cefaclor or amoxicillin in acute otitis media, and acute upper and lower respiratory tract infections. (R N Brogden, 1989)

A broad range of antibiotics helps in fighting various types of bacteria. (N J Leggett, 1990) Has an extended spectrum of antibacterial activity inhibiting beta-lactamase-producing respiratory pathogens. (H C Neu, 1993) The drug of choice for the treatment of respiratory tract infections. Inhibits the majority of pathogens, 90%, of Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis. (Neu, 1987) Effective treatment for pneumonia and acute bacterial exacerbations of bronchitis. (H C Neu, 1993) Better at both eradicating and preventing recurrences of group A streptococcus bacteria compared with penicillin V. (Ben JK Tan, 1995) Offers the additional benefit of covering beta-lactamase-producing strains of bacteria that are resistant to many penicillins. (D R Edelstein, 1993) A useful therapeutic option for the treatment of urinary tract infection with a success rate comparable to that of trimethoprim-sulfamethoxazole. (Ben JK Tan, 1995) Exhibits good activity against most pathogens causing urinary tract infections. (Modai, 1989) A suitable alternative to cefaclor or amoxicillin in acute otitis media, acute upper and lower respiratory tract infections. (R N Brogden, 1989)

A class of medications called penicillin-like antibiotics is used to treat infections caused by bacteria in different parts of the body. A penicillin derivative that has activity against both gram-positive and gram-negative bacteria. (Justin Evans) Exerts a bactericidal action against both Gram-positive and Gram-negative microorganisms by inhibiting the biosynthesis and repair of the bacterial cell wall. A promising agent for bacterial infections, such as chest infections (including pneumonia) and dental abscesses. A first-choice medicine to treat many bacterial infections. An effective antibiotic treatment for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. (Carl Llor, 2009)

A broad-spectrum, bactericidal antibiotic of the fluoroquinolone drug class that treats bacterial infections. (Podder & Sadiq, 2020) A valuable antimicrobial agent that has high levels of susceptibility among Gram-negative, Gram-positive including penicillin-resistant strains of Streptococcus pneumonia and atypical pathogens. (Antoni Torres, 2012) More active against gram-positive pathogens than ciprofloxacin. (Miriam Hurst, 2002) As effective as gatifloxacin, clarithromycin, azithromycin or amoxicillin/clavulanic acid in patients with mild to severe community-acquired pneumonia. (Miriam Hurst H. M., 2002) An effective therapy as intravenous imipenem/cilastatin in suspected bacteraemia patients. (Miriam Hurst H. M., 2002) A therapeutic regimen in patients with uncomplicated skin and skin structure infections, and complicated urinary tract infections. (Miriam Hurst H. M., 2002) Achieves 64.7% clinical success rate as compared with 41.2% with comparator treatment (imipenem/cilastatin followed by ciprofloxacin) in patients diagnosed with nosocomial pneumonia. (Alan M Tennenberg, 2006) Exhibits good clinical and microbiological efficacy for use in lower respiratory tract infections that are caused by Streptococcus pneumoniae. (Guoying Cao, 2020) Demonstrates antibacterial efficacy against a variety of infections, including upper and lower respiratory tract, genitourinary, obstetric, gynecological, and skin and soft tissues. (R Davis, 1994) An attractive option for the treatment of at-risk patients with serious respiratory tract infections including community-acquired pneumonia and acute exacerbations of chronic bronchitis. (Rafael Cantón, 2006)

A combi pack is used to prevent stomach and intestinal ulcers caused by bacterial infection with helicobacter pylori. Effectively eradicates helicobacter pylori infection in patients with peptic and duodenal ulcer disease. Ensures high rates of ulcer healing and helicobacter pylori eradication. Esomeprazole-based triple therapy demonstrates a higher eradication rate than pantoprazole-based regimen. Relieves acidity and discomfort related to the infection. Shows a more rapid onset of acid-suppressant effect than omeprazole. (Dr L. Laine, 2002)